

## **Completion of Share Purchase Plan**

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, today announced the completion of its Share Purchase Plan (SPP). The SPP provided AtCor shareholders the opportunity to support the key initiatives outlined in the company's strategic review update announced on 2 August 2017, following the recent \$825,000 share placement to institutions and sophisticated investors.

The SPP closed on Monday, 18 September 2017. Applications for \$341,000 of new fully paid ordinary shares were received, including \$80,000 from the company's Directors and affiliates. The total amount raised under the placement completed in August 2017 and the SPP is approximately \$1.175 million before costs. Taylor Collison acted as the lead manager for the placement and as underwriter for the SPP up to a value of \$270,000 (excluding purchases by Directors and affiliates).

Eligible SPP applicants will be issued new AtCor shares at \$0.027 per share. The new shares will be issued on 22 September 2017 with holding statements expected to be dispatched to participating shareholders on the same day. All new shares issued under the SPP will rank equally with existing ordinary shares of the Company.

The funds will be used to provide additional working capital to support the key initiatives outlined in the company's strategic review update announced on 2 August 2017. These include an increased focus on advancing strategic options, securing new sales and restructuring operations to maximise profitability.

AtCor Medical CEO Duncan Ross said: "We would like to thank shareholders for their participation in the share purchase plan. Since announcement of the strategic review update we have made progress to restructure the company, further reducing operating costs. We plan to bring costs into line with revenue in order to achieve sustainable profitability."

### **About AtCor Medical**

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor® system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor® is essential for hypertension diagnosis and management.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

*For further information, please contact (AtCor):*

Duncan Ross – AtCor Medical CEO  
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO  
+61 (2) 8815 8811

*Media enquiries to:*

Ashley Rambukwella – Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m. 0407 231 282  
or [a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)